Adhesion Gpcrs Are Widely Expressed Throughout The
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Strategies to Increase ß-Cell Mass Expansion
This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents ................................................................................................. -
Edinburgh Research Explorer
Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S. -
Reck and Gpr124 Activate Canonical Wnt Signaling To
RECK AND GPR124 ACTIVATE CANONICAL WNT SIGNALING TO CONTROL MAMMALIAN CENTRAL NERVOUS SYSTEM ANGIOGENESIS AND BLOOD-BRAIN BARRIER REGULATION by Chris Moonho Cho A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July 2018 © Chris Moonho Cho 2018 All rights reserved Abstract Canonical Wnt signaling plays a pivotal role in promoting central nervous system (CNS) angiogenesis and blood-brain barrier (BBB) formation and maintenance. Specifically, Wnt7a and Wnt7b are required for vascular development in the forebrain and ventral spinal cord. Yet, how these two ligands – among the 19 mammalian Wnts – are selectively communicated to Frizzled receptors expressed on endothelial cells (ECs) remains largely unclear. In this thesis, we propose a novel paradigm for Wnt specificity. We have identified two EC surface proteins – orphan receptor Gpr124, and more recently, GPI-anchored Reck (reversion-inducing cysteine-rich protein with Kazal motifs) – as essential receptor co-factors that assemble into a multi-protein complex with Wnt7a/7b and Frizzled for the development of the mammalian neurovasculature. Specifically, we show that EC-specific reduction in Reck impairs CNS angiogenesis and that EC-specific postnatal loss of Reck, combined with loss of Norrin, impairs BBB maintenance. We identify the critical domains of both Reck and Gpr124 that are required for Wnt activity, and demonstrate that these regions are important for ii direct binding and complex formation. Importantly, weakening this interaction by targeted mutagenesis reduces Reck-Gpr124 stimulation of Wnt7a signaling in cell culture and impairs CNS angiogenesis. Finally, a soluble Gpr124 probe binds specifically to cells expressing Frizzled (Fz), Wnt7a or Wnt7b, and Reck; and a soluble Reck probe binds specifically to cells expressing Fz, Wnt7a or Wnt7b, and Gpr124. -
Multi-Functionality of Proteins Involved in GPCR and G Protein Signaling: Making Sense of Structure–Function Continuum with In
Cellular and Molecular Life Sciences (2019) 76:4461–4492 https://doi.org/10.1007/s00018-019-03276-1 Cellular andMolecular Life Sciences REVIEW Multi‑functionality of proteins involved in GPCR and G protein signaling: making sense of structure–function continuum with intrinsic disorder‑based proteoforms Alexander V. Fonin1 · April L. Darling2 · Irina M. Kuznetsova1 · Konstantin K. Turoverov1,3 · Vladimir N. Uversky2,4 Received: 5 August 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published online: 19 August 2019 © Springer Nature Switzerland AG 2019 Abstract GPCR–G protein signaling system recognizes a multitude of extracellular ligands and triggers a variety of intracellular signal- ing cascades in response. In humans, this system includes more than 800 various GPCRs and a large set of heterotrimeric G proteins. Complexity of this system goes far beyond a multitude of pair-wise ligand–GPCR and GPCR–G protein interactions. In fact, one GPCR can recognize more than one extracellular signal and interact with more than one G protein. Furthermore, one ligand can activate more than one GPCR, and multiple GPCRs can couple to the same G protein. This defnes an intricate multifunctionality of this important signaling system. Here, we show that the multifunctionality of GPCR–G protein system represents an illustrative example of the protein structure–function continuum, where structures of the involved proteins represent a complex mosaic of diferently folded regions (foldons, non-foldons, unfoldons, semi-foldons, and inducible foldons). The functionality of resulting highly dynamic conformational ensembles is fne-tuned by various post-translational modifcations and alternative splicing, and such ensembles can undergo dramatic changes at interaction with their specifc partners. -
G Protein‐Coupled Receptors
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. -
Identification of Three Novel Mutations in FRMD7 Gene for X-Linked Idiopathic Congenital Nystagmus
Identification of Three Novel Mutations in FRMD7 gene for X-linked Idiopathic Congenital Nystagmus Xiao Zhang, Xianglian Ge, Ying Yu, Yilan Zhang, Yaming Wu, Yin Luan, Ji Sun, Jia Qu, Zi-Bing Jin and Feng Gu* Table S1. Capture Next Generation Sequencing of CASK gene Position: Position: Number Sequencing Chromosome Start Stop Length of tags Depth Mutation chrX 41379641 41379880 239 172 72.0 No chrX 41383186 41383305 119 80 67.2 No chrX 41390241 41390480 239 189 79.1 No chrX 41393939 41394058 119 175 147.1 No chrX 41394119 41394238 119 92 77.3 No chrX 41401882 41402061 179 106 59.2 No chrX 41412950 41413189 239 332 138.9 No chrX 41414811 41414930 119 95 79.8 No chrX 41416259 41416378 119 202 169.7 No chrX 41418928 41419167 239 511 213.8 No chrX 41420795 41420914 119 52 43.7 No chrX 41428900 41429019 119 11 9.2 No chrX 41437567 41437806 239 210 87.9 No chrX 41446140 41446259 119 54 45.4 No chrX 41448747 41448866 119 86 72.3 No chrX 41469110 41469337 227 223 98.2 No chrX 41481819 41481938 119 115 96.6 No chrX 41483466 41483585 119 293 246.2 No chrX 41485847 41485966 119 75 63.0 No chrX 41495813 41495932 119 73 61.3 No chrX 41519678 41519872 194 246 126.8 No chrX 41524498 41524737 239 252 105.4 No chrX 41530672 41530791 119 69 58.0 No chrX 41554860 41556059 1199 1932 161.1 No chrX 41586245 41587324 1079 1044 96.8 No chrX 41598613 41598732 119 27 22.7 No chrX 41604756 41604875 119 27 22.7 No chrX 41646424 41646543 119 124 104.2 No chrX 41712364 41712483 119 37 31.1 No chrX 41782152 41782271 119 5 4.2 No Table S2. -
GPCR Expression Profiles Were Determined Using
Supplemental Figures and Tables for Tischner et al., 2017 Supplemental Figure 1: GPCR expression profiles were determined using the NanoString nCounter System in 250 ng of pooled cell RNA obtained from freshly isolated CD4 T cells from naïve lymph nodes (CD4ln), spinal cord infiltrating CD4 T cells at peak EAE disease (CD4sc), and primary lung endothelial cells (luEC). Supplemental Figure 2: Array design and quality controls. A, Sorted leukocytes or endothelial cells were subjected to single‐cell expression analysis and re‐evaluated based on the expression of various identity‐defining genes. B, Expression of identity‐defining and quality control genes after deletion of contaminating or reference gene‐negative cells. Expression data are calculated as 2(Limit of detection(LoD) Ct – sample Ct) ; LoD Ct was set to 24. Supplemental Figure 3: Overview over GPCR expression frequencies in different freshly isolated immune cell populations and spinal cord endothelial cells as determined by single cell RT‐PCR. Abbreviations: CD4ln‐Tcon/CD4ln‐Treg, conventional (con) and regulatory (reg) CD4 T cells from lymph nodes (CD4ln) of naïve mice; CD4dr/CD4sc, CD4 T cells from draining lymph nodes (dr) or spinal cord (sc) at peak EAE disease; CD4spn2D/ CD4spn2DTh1/ CD4spn2DTh17, splenic CD4 T cells from 2D2 T cell receptor transgenic mice before (2D) and after in vitro differentiation towards Th1 (2DTh1) or Th17 (2DTh17); MonoSpn, splenic monocytes; CD11b_sc, spinal cord infiltrating CD11b‐ positive cells; sc_microglia, Ccr2neg,Cx3cr1pos microglia from spinal cord at peak disease; sc_macrophages, CCr2pos;Cx3cr1lo/neg macrophages from spinal cord at peak disease; BMDM_M1/BMDM_M2, bone marrow‐derived macrophages differentiated towards M1 or M2; ECscN and ECscEAE, spinal cord endothelial cells from naïve mice (N) and at peak EAE disease (EAE); SMC, smooth muscle cells from various vessel types (included as positive control to ascertain primer functionality). -
Supplementary Data, Ms Iring Et Al. Re-Revised
Supplementary Data András Iring et al., “Shear stress-induced endothelial adrenomedullin signaling regulates vascular tone and blood pressure” Supplementary Tables Supplementary Table 1. Target sequences of siRNAs used in the siRNA screen (Fig. 4A). Gene Target sequence (5´-3´) ADORA2A CGGAACAGCTCCCAGGTCT ADORA2A GCTGTTAGATCCTCCATGT ADORA2A GGCTTTCCACGGGTTCAGA ADORA2B GAGACTTCCGCTACACTTT ADORA2B GAGCTCATGGATCACTCAA ADORA2B GATGCAGCCACGAACGTGA ADRB1 CAGATCTGGTCATGGGTCT ADRB1 GTGTCATCGCCCTGGACCA ADRB1 CCATCTCGGCGCTGGTGTC ADRB2 CAAGTTCTACTTGAAGGAA ADRB2 CAACTTCTGGTGTGAGTTT ADRB2 GTCATCACAGCCATTGCCA CALCRL GATCAGTTCTGATACGCAA CALCRL GATACTCTCCGTAGTGCAT CALCRL GATTTATGATTTACCTATA CCRL1 GTATGAAGTGATCTGTATA CCRL1 GCTACTTCATCACGGCAAA CCRL1 GCATCAAACATCTGCATTT CCRL2 GACCCTACAATATTGTACT CCRL2 GCTTCTTTACCGGACTTCA CCRL2 CCTGTTGCTCTACTCCATA CELSR1 CTATGAGGAGAATCGAGTA CELSR1 GACTGAAGGTCCAGACGCA CELSR1 CCAACATCGCCACGCTGAA CELSR3 CCTTTGTAACCAGAGAGAT CELSR3 CAGCTTATGATCCAGATGT CELSR3 GCAATACCGGGAGACGCTT CXCR7 GCATGAGTGTGGATCGCTA CXCR7 GCTACGACACGCACTGCTA CXCR7 CTTTGGAGCAGAATGCCAA 2 ELTD1 CTCTTCTAATTCAACTCTT ELTD1 CAAGTTTATTACTAATGAT ELTD1 GTACCATACAGCTATAGTA FZD1 GTAACCAATGCCAAACTTT FZD1 GATTAGCCACCGAAATAAA FZD1 CAGTGTTCCGCCGAGCTCA FZD2 CGCTTTGCGCGCCTCTGGA FZD2 GACATGCAGCGCTTCCGCT FZD2 CGCACTACACGCCGCGCAT FZD4 GTATGTGCTATAATATTTA FZD4 CCATTGTCATCTTGATTAT FZD4 CCAACATGGCAGTGGAAAT FZD5 GGATTTAAGGCCCAGTTTA FZD5 GACCATAACACACTTGCTT FZD5 CAAGTGATCCTGGGAAAGA FZD6 GCATTGTATCTCTTATGTA FZD6 GTGCTTACTGAGTGTCCAA FZD6 CCAATTACTGTTCCCAGAT FZD8 CCATCTGCCTAGAGGACTA -
G Protein-Coupled Receptors at the Crossroad Between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts
International Journal of Molecular Sciences Review G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts Ernestina M. De Francesco 1,2, Federica Sotgia 3, Robert B. Clarke 2, Michael P. Lisanti 3 and Marcello Maggiolini 1,* ID 1 Department of Pharmacy, Health and Nutrition Sciences, University of Calabria via Savinio, 87036 Rende, Italy; [email protected] 2 Breast Cancer Now Research Unit, Division of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Wilmslow Road, Manchester M20 4GJ, UK; [email protected] 3 Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre, University of Salford, Greater Manchester M5 4WT, UK; [email protected] (F.S.); [email protected] (M.P.L.) * Correspondence: [email protected]; Tel.: +39-0984-493076 Received: 30 October 2017; Accepted: 11 December 2017; Published: 14 December 2017 Abstract: G protein-coupled receptors (GPCRs) have been implicated in transmitting signals across the extra- and intra-cellular compartments, thus allowing environmental stimuli to elicit critical biological responses. As GPCRs can be activated by an extensive range of factors including hormones, neurotransmitters, phospholipids and other stimuli, their involvement in a plethora of physiological functions is not surprising. Aberrant GPCR signaling has been regarded as a major contributor to diverse pathologic conditions, such as inflammatory, cardiovascular and neoplastic diseases. In this regard, solid tumors have been demonstrated to activate an angiogenic program that relies on GPCR action to support cancer growth and metastatic dissemination. Therefore, the manipulation of aberrant GPCR signaling could represent a promising target in anticancer therapy. -
Expression Map of 78 Brain-Expressed Mouse Orphan Gpcrs Provides a Translational Resource for Neuropsychiatric Research
ARTICLE DOI: 10.1038/s42003-018-0106-7 OPEN Expression map of 78 brain-expressed mouse orphan GPCRs provides a translational resource for neuropsychiatric research Aliza T. Ehrlich1,2, Grégoire Maroteaux2,5, Anne Robe1, Lydie Venteo3, Md. Taufiq Nasseef2, 1234567890():,; Leon C. van Kempen4,6, Naguib Mechawar2, Gustavo Turecki2, Emmanuel Darcq2 & Brigitte L. Kieffer 1,2 Orphan G-protein-coupled receptors (oGPCRs) possess untapped potential for drug dis- covery. In the brain, oGPCRs are generally expressed at low abundance and their function is understudied. Expression profiling is an essential step to position oGPCRs in brain function and disease, however public databases provide only partial information. Here, we fine-map expression of 78 brain-oGPCRs in the mouse, using customized probes in both standard and supersensitive in situ hybridization. Images are available at http://ogpcr-neuromap.douglas. qc.ca. This searchable database contains over 8000 coronal brain sections across 1350 slides, providing the first public mapping resource dedicated to oGPCRs. Analysis with public mouse (60 oGPCRs) and human (56 oGPCRs) genome-wide datasets identifies 25 oGPCRs with potential to address emotional and/or cognitive dimensions of psychiatric conditions. We probe their expression in postmortem human brains using nanoString, and included data in the resource. Correlating human with mouse datasets reveals excellent suitability of mouse models for oGPCRs in neuropsychiatric research. 1 IGBMC, Institut Génétique Biologie Moléculaire Cellulaire, Illkirch, France. 2 Douglas Mental Health University Institute and McGill University, Department of Psychiatry, Montreal, Canada. 3 Label Histologie, 51100 Reims, France. 4 Lady Davis Institute for Medical Research, Jewish General Hospital and McGill University, Department of Pathology, Montreal, Canada. -
Recombinant Human TEM5/GPR124 His‑Tag Catalog Number: 10206-TE
Recombinant Human TEM5/GPR124 His‑tag Catalog Number: 10206-TE DESCRIPTION Source Human embryonic kidney cell, HEK293-derived human TEM5/GPR124 protein Ala27-Arg359, with C-terminal 6-His tag Accession # AAO27354 N-terminal Sequence Ala27 Analysis Predicted Molecular 36 kDa Mass SPECIFICATIONS SDS-PAGE 53-60 kDa, under reducing conditions Activity Measured by its binding ability in a functional ELISA. When Recombinant Human RECK Fc Chimera (Catalog # 10309-RE) is immobilized at 2 µg/mL (100 µL/well), Recombinant Human TEM5/GPR124 His-tag (Catalog # 10206-TE) binds with an ED50 of 1‑8 μg/mL. Endotoxin Level <0.10 EU per 1 μg of the protein by the LAL method. Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. PREPARATION AND STORAGE Reconstitution Reconstitute at 500 μg/mL in PBS. Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution. DATA Binding Activity SDS-PAGE When Recombinant 2 μg/lane of Recombinant Human Human RECK Fc TEM5/GPR124 His-tag (Catalog # 10206- Chimera (Catalog # TE) was resolved with SDS-PAGE under 10309-RE) is reducing (R) and non-reducing (NR) immobilized conditions and visualized by Coomassie® at 2 μg/mL Blue staining, showing bands at 53-60 kDa. -
Normalized Expression Values *
Normalized expression values 0.0 0.2 0.4 0.6 0.8 1.0 1.2 PLCG1 * T CD5 MP T B TCF7 cDC UBASH3A BCL11B C5AR1 * MP TLR4 CXCR5 B CD79B VPREB3 XCR1 CADM1 BEND5 * ARGHAP22 * cDC CIITA ZBTB46 FLT3 PLEKHA5 Figure S1. qPCR analysis of the core gene expression signature of cDC, MP, B and T cells in the chicken cell suBsets. RNA from cDC, MP, T and B cells of 2 disUnct pools of 4 chicken spleen was subjected to qPCR detecUon of the core gene expression signatures of immune cell subsets established in Fig. 3 and of transcripts from the mouse and human gene subset selected compendia that could not be detected on the array due to defecUve probes, i.e. ARGHAP22, BEND5, C5AR1, and PLCG1 (labeled by a star on the figure). Data are represented as the mean and SD of relave gene expression levels normalized to GAPDH expression and the maximal expression across the cell types was set to 1 (independent experimental duplicates). B cell T cell cDC Monocyte/MP Chicken Human Mouse Figure S2. Unsupervised hierarchical clustering of orthologous immune response genes across chicken, human and mouse reveals globally conserved clusters of lymphoïd- specific and myeloïd- specific genes. Heatmap of cross-normalized expression profiles for immune response genes present on all three species arrays and regulated at least 2 folds across all cell suBsets, including chicken B cells (c_B), T cells (c_CD3), MP (c_MP) and cDC (c_cDC), human B cells (h_B), T cells (h_CD4_T and h_CD8_T), monocyte-derived MP (h_MoMP), peripheral blood mononucleated cell-derived MP (h_PBMC_MP), non-classical monocytes (h_non- classical_MO), classical monocytes (h_classical_MO), BDCA3+ cDC (h_BDCA3), BDCA1+ cDC (h_BDCA1), murine B cells (m_B), T cells (m_CD4_T and m_CD8_T), peritoneal cavity MP (m_PC_MPII-480HI), lung MP (m_LU_MP), non-classical monocytes (m_non-classical_MO), classical monocytes (m_classical_MO), splenic CD8α+ cDC (m_SP_DC1), suBcutaneous lymph node CD8α+ cDC (m_LN_DC1), splenic CD11B+ cDC (m_SP_DC2), suBcutaneous lymph node CD11B+ cDC (m_LN_DC2).